Paroxetine and CYP2D6: Mechanism and Clinical Implications
Paroxetine is a potent mechanism-based inhibitor of CYP2D6 that saturates this enzyme early during dosing in >90% of patients, creating a functional "phenocopy" that converts extensive metabolizers to poor metabolizers and dramatically increases plasma concentrations of co-administered CYP2D6 substrates by 2- to 8-fold. 1
Mechanism of CYP2D6 Inhibition
Paroxetine inhibits CYP2D6 through mechanism-based (irreversible) inhibition, not simple competitive inhibition. The drug forms a metabolite intermediate complex with the enzyme, likely through metabolism of its methylenedioxy substituent, resulting in an approximately 8-fold reduction in IC50 when preincubated with microsomes (0.34 vs 2.54 μM) 2. This distinguishes paroxetine from other SSRI inhibitors like fluoxetine and quinidine, which do not exhibit this preincubation-dependent potentiation 2.
The FDA label explicitly states that in most patients (>90%), the CYP2D6 isozyme is saturated early during dosing with paroxetine 1. This saturation creates what guidelines describe as an "auto-phenocopy"—drug-induced conversion of normal metabolizers to poor metabolizers independent of genetic status 3.
Clinical Impact on Co-administered CYP2D6 Substrates
Magnitude of Drug Interactions
The FDA label documents specific, clinically significant interactions 1:
- Desipramine (tricyclic antidepressant): Cmax increased 2-fold, AUC increased 5-fold, half-life increased 3-fold with paroxetine 20 mg daily
- Risperidone (antipsychotic): Plasma concentrations increased approximately 4-fold, with active moiety increased 1.4-fold
- Atomoxetine (ADHD medication): AUC increased 6- to 8-fold, Cmax increased 3- to 4-fold 4
- Perphenazine (antipsychotic): Peak concentrations increased 2- to 13-fold, associated with significant increases in CNS side effects including oversedation, extrapyramidal symptoms, and psychomotor impairment 5
- Metoprolol (beta-blocker): AUC increased 3- to 5-fold, with significant decreases in systolic blood pressure and heart rate; case reports document bradycardia and atrioventricular block 6
Critical Safety Considerations
The FDA contraindication states that paroxetine and thioridazine must never be co-administered due to risk of serious ventricular arrhythmias and sudden death from elevated thioridazine levels 1.
The FDA has issued safety labeling changes warning that fluoxetine (and by extension, paroxetine as a CYP2D6 inhibitor) should be used with caution in patients with conditions predisposing to QT prolongation, including CYP2D6 poor metabolizer status and co-administration of CYP2D6 inhibitors 3.
Impact of Patient CYP2D6 Genotype
The degree of inhibition varies significantly based on baseline CYP2D6 metabolizer status:
- Extensive metabolizers (EMs): Experience the greatest impact, with paroxetine reducing CYP2D6 activity by 58% for substrates like aripiprazole 7
- Intermediate metabolizers (IMs): Experience less pronounced inhibition (23% reduction) because they have lower baseline CYP2D6 activity 7
- Poor metabolizers (PMs): Already have minimal CYP2D6 activity, so paroxetine adds little additional inhibition
For paroxetine itself, CYP2D6 genotype profoundly affects exposure: PMs have 3.8-fold higher concentration-to-dose ratios than EMs, while IMs have 2.2-fold higher ratios 8. Single-dose studies show paroxetine AUC was 7-fold higher in PMs vs EMs, though this declined to 1.7-fold with chronic dosing due to enzyme saturation 3.
Practical Management Recommendations
When Paroxetine is Co-prescribed with CYP2D6 Substrates:
Avoid the combination entirely when possible—select alternative antidepressants with minimal CYP2D6 inhibition (e.g., citalopram, escitalopram, sertraline) or alternative medications for the co-morbid condition 6
If combination is unavoidable:
- Reduce the dose of the CYP2D6 substrate before initiating paroxetine or when adding paroxetine to existing therapy
- For atomoxetine: FDA label recommends initiating at reduced dose when given with paroxetine 1
- For tricyclic antidepressants: Monitor plasma TCA concentrations and reduce TCA dose as needed 1
- For metoprolol: Consider 50-75% dose reduction and monitor closely for bradycardia, hypotension, and heart block 6
Monitor intensively for adverse effects specific to the substrate drug:
- Beta-blockers: Heart rate, blood pressure, signs of heart block
- Antipsychotics: Extrapyramidal symptoms, sedation, QT prolongation
- TCAs: Anticholinergic effects, cardiac conduction abnormalities
Special Populations Requiring Dose Adjustment:
CYP2D6 poor metabolizers taking paroxetine: Consider 25% of standard starting dose 8
CYP2D6 intermediate metabolizers taking paroxetine: Consider 50% of standard starting dose 8
Elderly patients (≥65 years): Have 2.9-fold increased paroxetine exposure independent of genotype; reduce initial dose 8
Critical Pitfalls to Avoid
Assuming all SSRIs have equivalent CYP2D6 inhibition: Paroxetine and fluoxetine are potent inhibitors, while citalopram, escitalopram, and sertraline have minimal effects 9
Failing to anticipate the time course: CYP2D6 inhibition by paroxetine occurs early (within days) and persists throughout treatment due to mechanism-based inhibition 2, 10
Overlooking tamoxifen interaction: Paroxetine inhibition of CYP2D6 reduces conversion of tamoxifen to its active metabolite endoxifen, potentially reducing tamoxifen efficacy in breast cancer treatment—avoid this combination 1
Ignoring CYP2C19 contribution: CYP2C19 intermediate and poor metabolizers have 1.6-fold higher paroxetine exposure, which may compound drug interaction risk 8
Underestimating clinical consequences: Case reports document fatalities from CYP2D6-related drug accumulation, including a child death from high-dose fluoxetine in a PM, and cardiac arrest from venlafaxine accumulation in a PM 3